Skip to search boxSkip to navigationSkip to main content

Acellular fraction from malignant effusions has cytotoxicity in breast cancer cells

  • Javier Vargas-Villarreal
    ,
  • Marlid Cruz-Ramos
    ,
  • Alba Espino-Ojeda
    ,
  • Hugo Gutierrez-Hermosillo
    ,
  • Enrique Díaz DE LEON-GONZALEZ
    ,
  • Ofelia Monsivais-Diaz
  • Universidad de Monterrey
    ,
  • Instituto Mexicano del Seguro Social
    ,
  • Universidad Autónoma de Madrid
    ,
  • Instituto Tecnologico de Estudios Superiores de Monterrey
    ,
  • Aranda de la Parra Hospital
    ,
Research Output: Contribution to journal Article Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Publication metrics

Metrics

SciVal
Author count
11
SciVal
Paper percentile
21

Abstract

Malignant ascites (MA) and malignant pleural effusion (MPE) are frequently developed in patients with metastatic cancer; however, the biological properties of these fluids have not been clarified. The present study explored the biological role of a low molecular fraction derived from malignant effusions on the activation of peripheral blood mononuclear cells and on the proliferation of breast cancer cells and fibroblast 55x cells. A <10-kDa fraction from effusions of 41 oncological patients and 34 individuals without cancer was purified, and its potential role in inhibiting nitric oxide (NO) production on lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells was explored, as well as its cytotoxicity on MCF-7 breast cancer cells and fibroblast 55x cells. A significant decrease in NO production was observed in the <10-kDa fraction from malignant effusions. In addition, the acellular fraction from MA decreased the viability of breast cancer cells without affecting human fibroblasts. These data support the presence of low molecular weight molecules in malignant samples with a specific role in inhibiting the defense mechanisms of peripheral blood mononuclear cells and decreasing the viability of breast cancer cells in vitro.

Publication Information

Output type

Research Output: Contribution to journal Article Peer-review

Original language

English

Article number

106

Journal (Volume, Issue Number)

Molecular and Clinical Oncology (Volume 14, Issue 5)

Publication milestones

  • Published - 2021

Publication status

Published - 2021

ISSN

2049-9450

Publication IDs

  • Scopus: 85103860663
  • PubMed: 33796293

Funding Details

The present study was supported by the Instituto Mexicano del Seguro Social (grant no. FIS/IMSS/PROT/G 2006/1A/I/080).
FundersFunding numbers
IMSS
FIS/IMSS/PROT/G 2006/1A/I/080